Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 6Prostatic Neoplasms 3Lymphoma, Follicular 3Leukemia, Lymphocytic, Chronic, B-Cell 3Small Cell Lung Carcinoma 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Waldenstrom Macroglobulinemia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Laryngeal Neoplasms 1Hormone Refractory Prostate Cancer 1Gliosarcoma 1Glioblastoma 1Extensive Stage Small Cell Lung Cancer 1Disease 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Brain Neoplasms 1Adrenocortical Carcinoma 1

Interventions

Dexamethasone 5Magnetic Resonance Spectroscopy 4Cyclophosphamide 4Blood Specimen Collection 4Surveys and Questionnaires 3Prednisone 3Melphalan 3Lenalidomide 3Biopsy, Fine-Needle 3fluciclovine F-18 2carfilzomib 2Positron-Emission Tomography 2Mammography 2Injections 2Immunohistochemistry 2Gemcitabine 2Cytarabine 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2weifuchun 1vistusertib 1venetoclax 1technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid) 1ricolinostat 1pomalidomide 1phosphoribosylformylglycinamidine synthetase 1pembrolizumab 1ofatumumab 1obinutuzumab 1lortalamine 1irinotecan sucrosofate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Disease × gossypol acetic acid × Clear all
NCT00571675 2010-11-09

A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)

Ascenta Therapeutics

Phase 2 Completed
220 enrolled
Genitourinary

Disease, Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡